Bio-Rad Laboratories Inc (BIO)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.69B
Last updated: Nov 17, 2026 at 4:20 PM ET
Bio-Rad Laboratories Inc (BIO) Statistics
Bio-Rad Laboratories (BIO) has a market cap of $9.69B and an enterprise value of $10.43B. It kept 39.45% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 7.62% above the market cap, as debt exceeds cash.
| Market Cap | $9.69B |
|---|---|
| Enterprise Value | $10.43B |
| Latest price (Nov 17, 2026) | $358.24 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.7x and 1.3x. Its year-end P/E ranged from 27.4x to 191.9x from 2016 to 2025.
| P/E Ratio | 37.0x |
|---|---|
| Forward P/E | 36.9x |
| P/S Ratio | 3.7x |
| Forward P/S | 3.8x |
| P/B Ratio | 1.3x |
| P/TBV Ratio | 1.4x |
| P/FCF Ratio | 24.4x |
| P/OCF Ratio | 18.2x |
| PEG Ratio | 15.8 |
Enterprise Valuation
Counting debt and cash, the company is valued at 22.0x EBITDA and 26.3x free cash flow.
| EV / Earnings | 10.2x |
|---|---|
| EV / Sales | 4.0x |
| EV / EBITDA | 22.0x |
| EV / FCF | 26.3x |
Price Statistics
The stock is up 14.40% over 52 weeks and trades 3.70% below its 50-day average.
| Beta (1Y) | 0.73 |
|---|---|
| 52-Week Change | +14.40% |
| 1-Month Change | +1.54% |
| 3-Month Change | -1.65% |
| 6-Month Change | +27.46% |
| 5-Year Change | -53.17% |
| 10-Year Change | +135.44% |
| Total Return (1Y) | +14.40% |
| Total Return (3Y CAGR) | +6.17% |
| Total Return (5Y CAGR) | -14.25% |
| Return vs SPY (1Y) | +4.84% |
| Max Drawdown (1Y) | -27.24% |
| Max Drawdown (3Y) | -42.14% |
| Sharpe Ratio (1Y) | 0.42 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $372.00 |
| 200-Day Average | $317.63 |
| 52-Week Range | $236.73 to $396.23 |
| RSI (14 Days) | 41.2 |
| Average Volume (20 Days) | 253.29K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.18x current liabilities, and total debt is 0.16x shareholder equity.
| Current Ratio | 3.18x |
|---|---|
| Quick Ratio | 2.37x |
| Debt / Equity | 0.16x |
| Debt / EBITDA | 2.57x |
| Debt / FCF | 3.06x |
| Interest Coverage | 9.60x |
Returns and Efficiency
Return on invested capital is 4.12% over the last 12 months, against a 5-year average of 3.02%.
| Return on Equity (ROE) | 13.45% |
|---|---|
| Return on Assets (ROA) | 9.49% |
| Return on Invested Capital (ROIC) | 4.12% |
| ROE (5Y Average) | -6.36% |
| ROA (5Y Average) | -4.13% |
| ROIC (5Y Average) | 3.02% |
| Asset Turnover | 0.25x |
| Inventory Turnover | 1.62x |
| Receivables Turnover | 6.00x |
| Cash Conversion Cycle | 247 days |
Taxes
Income tax took 22.52% of pretax income over the last 12 months.
| Income Tax (TTM) | $297.30M |
|---|---|
| Effective Tax Rate | 22.52% |
Scores
BIO has an Altman Z-Score of 3.53, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.53 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $2.59B over the last 12 months is up 1.38% from the 12 months before.
| Revenue | $2.59B |
|---|---|
| Revenue Growth (YoY) | +1.38% |
| Gross Profit | $1.33B |
| Operating Income | -$61.90M |
| Pretax Income | $1.32B |
| Net Income | $1.02B |
| Reported EPS (TTM) | $9.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 70.50% of the $10.78B in total assets.
| Cash and Equivalents | $465.30M |
|---|---|
| Total Debt | $1.20B |
| Net Debt | $738.70M |
| Net Debt Per Share | $27.58 |
| Working Capital | $2.11B |
| Shareholder Equity | $7.60B |
| Book Value Per Share | $283.91 |
| Tangible Book Value | $6.93B |
| Tangible Book Per Share | $258.61 |
| Total Assets | $10.78B |
| Total Liabilities | $3.18B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $139.00M of capital spending, operating cash flow left $393.00M of free cash flow.
| Operating Cash Flow | $532.00M |
|---|---|
| Capital Expenditures | $139.00M |
| Free Cash Flow | $393.00M |
| FCF Per Share | $18.11 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2.39%, against a 5-year average of 11.86%.
| Gross Margin | 51.26% |
|---|---|
| Operating Margin | -2.39% |
| Pretax Margin | 50.92% |
| Net Margin | 39.45% |
| FCF Margin | 15.16% |
| Gross Margin (5Y Average) | 54.20% |
| Operating Margin (5Y Average) | 11.86% |
| Net Margin (5Y Average) | -10.04% |
Growth
Revenue fell 2.68% a year over 3 years, and EPS 11.33% a year.
| Revenue Growth (3Y CAGR) | -2.68% |
|---|---|
| Revenue Growth (5Y CAGR) | +0.29% |
| EPS Growth (3Y CAGR) | -11.33% |
| EPS Growth (5Y CAGR) | -1.19% |
| FCF Growth (5Y CAGR) | -4.69% |
| Operating Income Growth (3Y CAGR) | -53.93% |
| Book Value Per Share Growth (2Y CAGR) | -4.63% |
| Tangible Book Per Share Growth (2Y CAGR) | -5.53% |
Dividends and Yields
BIO does not pay a dividend. Its free cash flow yield is 4.10%.
| Earnings Yield | 2.70% |
|---|---|
| FCF Yield | 4.10% |
| Buyback Yield | 0.67% |
| Shareholder Yield | 0.67% |
Stock Splits
The last split was a 2-for-1 forward split on Mar 8, 2002.
| Last Split Date | Mar 8, 2002 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, BIO has the 3rd highest P/E.
P/E RatioPeer median 23.6x
P/S RatioPeer median 3.5x
ROICPeer median 7.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.91%
| P/E Ratio | 37.0x vs 23.6x median |
|---|---|
| P/S Ratio | 3.7x vs 3.5x median |
| ROIC | 4.12% vs 7.96% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1.38% vs +9.91% median |
Analyst Forecast
Consensus estimates put revenue growth at 0.46% and EPS growth at -0.07% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +0.46% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -0.07% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BIO
What is BIO's market cap?
Bio-Rad Laboratories has a market cap of $9.69B. Its enterprise value, which adds debt and subtracts cash, is $10.43B.
What is BIO's P/E ratio?
Bio-Rad Laboratories has a trailing P/E ratio of 37.0x and a forward P/E of 36.9x.
How many shares of BIO are outstanding?
Bio-Rad Laboratories has 26.78M shares outstanding. The count is down 0.53% from a year earlier.
Does BIO pay a dividend?
No. Bio-Rad Laboratories does not pay a dividend.
How much debt does BIO have?
Bio-Rad Laboratories has $1.20B of total debt and $465.30M of cash and equivalents, a net debt position of $738.70M.
BIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors